300765 CSPC Innovation Pharmaceutical
- 22.92
- +0.17+0.75%
CSPC Innovation Pharmaceutical News
CSPC Innovation Pharmaceutical: Explanation of the purchase and sale of assets within the last 12 months prior to this trade.
CSPC Innovation Pharmaceutical: Explanation on this trade that complies with Article 11 and Article 43 of the Measures for the Administration of Major Asset Restructuring of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation that the adjustment of the pricing reference date for this trade proposal does not constitute a significant adjustment.
CSPC Innovation Pharmaceutical: This trade complies with the regulations of Article 4 of the Supervision Requirements for Major Asset Restructurings of Listed Companies in Compliance with the Guidelines for the Supervision of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation of the confidentiality measures and system adopted for this trade.
CSPC Innovation Pharmaceutical: This trade complies with relevant regulations of the Securities Issuance and Registration Management Measures for Listed Companies.
CSPC Innovation Pharmaceutical: Regarding this trade, it is expected to constitute a significant asset restructuring under Article 12 of the "Management Measures for Major Asset Restructuring of Listed Companies", but it does not constitute a case of restructuring for listing under Article 13.
CSPC Innovation Pharmaceutical: The explanation of this transaction is in compliance with Article 18 and 21 of the Measures for the Continuous Supervision of Listed Companies on the Growth Enterprise Market (Trial), as well as Article 8 of the Shenzhen Stock Exchange's Rules for the Review of Major Asset Restructurings of Listed Companies.
CSPC Innovation Pharmaceutical: Explanation regarding the completeness, compliance, and effectiveness of the legal procedures and submission of legal documents for this trade.
CSPC Innovation Pharmaceutical: Regarding this trade, the relevant parties do not meet the requirements outlined in Article 12 of the "Guidelines for the Supervision of Listed Companies No. 7 - Supervision of Unusual Stock Trades Related to Major Asset Restructuring of Listed Companies" and Article 30 of the "Self-Regulatory Guidelines for Listed Companies in Shenzhen Stock Exchange No. 8 - Major Asset Restructuring (Revised in 2023)" and may not participate in the major asset restructuring of listed companies.
New Novus: Explanation on the pricing reference date and issuance price adjustments of this transaction plan do not constitute a major adjustment
New Novus: Explanation on the completeness of the transaction\'s compliance with legal procedures and the effectiveness of submitting legal documents
New Novus: Explanation that this transaction complies with the provisions of Articles 18 and 21 of the “Measures for Continued Supervision of GEM Listed Companies (Trial)” and Article 8 of the “Shenzhen Stock Exchange Listed Companies Major Asset Reorganiz
New Novus: Explanation on the completeness of the transaction\'s compliance with legal procedures and the effectiveness of submitting legal documents
New Novus: Explanation of how this transaction is expected to constitute a major asset restructuring as stipulated in Article 12 of the “Administrative Measures on the Major Asset Reorganization of Listed Companies”, but not the restructuring and listing a
New Novus: Explanation of the confidentiality measures and confidentiality system adopted for this transaction
New Novus: Instructions on how this transaction complies with the provisions of Articles 11 and 43 of the “Administrative Measures on Major Asset Reorganization of Listed Companies”
New Novus: Explanation that this transaction complies with the provisions of section 4 of the “Supervisory Guidelines for Listed Companies No. 9 - Regulatory Requirements for Listed Companies to Plan and Implement Major Asset Restructurings”
New Novus: Explanation of stock price fluctuations of listed companies before the transaction was first disclosed
New Novus: Explanation of the purchase and sale of assets within 12 months prior to this transaction
Analysis
Price Target
No Data
